Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 249 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malignant Pleural Neoplasm Clear all
Completed Phase 2 Interventional Results available

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

NCT01160458
View directory record Official record
Conditions
Pleural Mesothelioma, Peritoneal Mesothelioma
Interventions
IMC-A12
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 14, 2026, 9:42 AM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897
View directory record Official record
Conditions
Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions
THOR-707, Pembrolizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

A Study of LY3023414 in Participants With Advanced Cancer

NCT01655225
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
Interventions
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 14, 2026, 9:42 AM EDT
Active, not recruiting Phase 1 Interventional

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07118176
View directory record Official record
Conditions
Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT00027703
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 4 Interventional

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

NCT00978939
View directory record Official record
Conditions
Pleural Effusion, Malignant
Interventions
Standard Drainage Instructions, Aggressive Drainage Instructions
Other
Lead sponsor
Duke University
Other
Eligibility
19 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

NCT00055705
View directory record Official record
Conditions
Cancer
Interventions
PV701
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers

NCT04662645
View directory record Official record
Conditions
Caregiver, Malignant Pleural Neoplasm, Metastatic Thymic Carcinoma, Recurrent Lung Carcinoma, Recurrent Thymic Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Palliative Therapy, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

NCT03175172
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
CRS-207, Pembrolizumab
Biological
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 14, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

NCT05960773
View directory record Official record
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
Decitabine/cedazuridine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

NCT00003263
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
3
States / cities
Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

NCT00003508
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
1 Year to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC

NCT00250978
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab with chemotherapy, Pleur-XTM catheter placement
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2008 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated Phase 3 Interventional Results available

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
277
States / cities
Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated No phase listed Observational

Staging Procedures to Diagnose Malignant Pleural Mesothelioma

NCT02648763
View directory record Official record
Conditions
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Malignant Pleural Effusion With ZD6474

NCT00402896
View directory record Official record
Conditions
Lung Cancer, Pleural Effusion
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 14, 2026, 9:42 AM EDT
Enrolling by invitation No phase listed Observational

Biomarker Levels During Indwelling Pleural cAtheter Sample Testing

NCT02092155
View directory record Official record
Conditions
Malignant Pleural Effusions
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated Phase 1 Interventional

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

NCT01445392
View directory record Official record
Conditions
Mesothelioma
Interventions
Multicycle SS1P, Pemetrexed, Cisplatin, Single cycle SS1P
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 14, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

Olaparib in Patients With HRD Malignant Mesothelioma

NCT04515836
View directory record Official record
Conditions
Mesothelioma, Homologous Recombination Deficiency
Interventions
Olaparib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 14, 2026, 9:42 AM EDT
Recruiting Phase 1 Interventional

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

NCT03760575
View directory record Official record
Conditions
Mesotheliomas Pleural
Interventions
Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin, Pemetrexed
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 14, 2026, 9:42 AM EDT
Terminated No phase listed Observational

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

NCT02613312
View directory record Official record
Conditions
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 14, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

NCT01503177
View directory record Official record
Conditions
Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
oncolytic measles virus encoding thyroidal sodium iodide symporter, laboratory biomarker analysis, single photon emission computed tomography, computed tomography
Biological · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 14, 2026, 9:42 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

NCT02153229
View directory record Official record
Conditions
Epitheliod Malignant Pleural Mesothelioma
Interventions
Photodynamic Therapy, Radical Pleurectomy, Chemotherapy, Photofrin 2.0 mg/kg
Radiation · Procedure · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 14, 2026, 9:42 AM EDT